兔抗CBL (phospho-Tyr700)多克隆抗體

Background:

Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.

Applications:

WB, IHC, IF

Name of antibody:

CBL (phospho-Tyr700)

Immunogen:

Synthetic peptide of human CBL (phospho-Tyr700)

Full name:

Cbl proto-oncogene, E3 ubiquitin protein ligase (phospho-Tyr700)

Synonyms：

CBL2; NSLL; C-CBL; RNF55; FRA11B

SwissProt:

P22681

IHC positive control:

Human breast carcinoma

IHC Recommend dilution:

50-100

WB Predicted band size:

120 kDa

WB Positive control:

HT29 cells treated with UV

WB Recommended dilution:

500-1000

IF Positive control:

Hela cells

IF Recommended dilution

100-200